A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy.
Publication
, Journal Article
Hussain, M; Rathkopf, DE; Liu, G; Armstrong, AJ; Kelly, WK; Ferrari, AC; Hainsworth, JD; Yang, L; Schwartz, JD; Higano, CS
Published in: JOURNAL OF CLINICAL ONCOLOGY
February 10, 2012
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
February 10, 2012
Volume
30
Issue
5
Publisher
AMER SOC CLINICAL ONCOLOGY
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Hussain, M., Rathkopf, D. E., Liu, G., Armstrong, A. J., Kelly, W. K., Ferrari, A. C., … Higano, C. S. (2012). A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy. JOURNAL OF CLINICAL ONCOLOGY, 30(5). https://doi.org/10.1200/jco.2012.30.5_suppl.97
Hussain, Maha, Dana E. Rathkopf, Glenn Liu, Andrew J. Armstrong, William Kevin Kelly, Anna C. Ferrari, John D. Hainsworth, Ling Yang, Jonathan D. Schwartz, and Celestia S. Higano. “A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy.” JOURNAL OF CLINICAL ONCOLOGY 30, no. 5 (February 10, 2012). https://doi.org/10.1200/jco.2012.30.5_suppl.97.
Hussain M, Rathkopf DE, Liu G, Armstrong AJ, Kelly WK, Ferrari AC, et al. A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy. JOURNAL OF CLINICAL ONCOLOGY. 2012 Feb 10;30(5).
Hussain, Maha, et al. “A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy.” JOURNAL OF CLINICAL ONCOLOGY, vol. 30, no. 5, AMER SOC CLINICAL ONCOLOGY, Feb. 2012. Wos, doi:10.1200/jco.2012.30.5_suppl.97.
Hussain M, Rathkopf DE, Liu G, Armstrong AJ, Kelly WK, Ferrari AC, Hainsworth JD, Yang L, Schwartz JD, Higano CS. A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2012 Feb 10;30(5).
Published In
JOURNAL OF CLINICAL ONCOLOGY
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
February 10, 2012
Volume
30
Issue
5
Publisher
AMER SOC CLINICAL ONCOLOGY
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences